Predict to prevent pre-eclampsia
PerkinElmer’s DELFIA® Xpress PlGF 1-2-3™ assay, used in the ground-breaking ASPRE study (Rolnik et al, 2017), is the most sensitive first trimester screening assay for pre-eclampsia to date. Screening with DELFIA® Xpress PlGF 1-2-3™ assay before 13+6 weeks of gestation in combination with other biophysical markers and established risk factors, high risk women that are likely to develop preterm pre-eclampsia later in their pregnancy can be identified.
Aid in Diagnosis of Pre-eclampsia in the 2nd and 3rd trimester
During second and third trimesters of pregnancy, the DELFIA® Xpress sFlt-1 kit can be used for predicting the onset of pre-eclampsia and to manage pre-eclampsia in combination with the PlGF 1-2-3™ assay as a ratio of concentrations and with other clinical factors.
In addition to DELFIA® Xpress, the PlGF 1-2-3™ assay is also available for PerkinElmer’s AutoDELFIA® and Victor2™ D platforms. PerkinElmer’s biochemistry assays and supporting instruments are complemented by essential items such as human serum controls to ensure the integrity of results. We also supply dedicated pre-eclampsia screening software for risk calculations. Together, these products constitute a complete solution for pre-eclampsia management.
Products may not be licensed in accordance with the laws in all countries, such as the United States. Please check with your local representative for availability.